Market evolution: Heparin (CN 30019091) — 2015–2025

Introduction

Heparin and its salts (CN 30019091) are critical pharmaceutical substances used primarily as anticoagulants in surgery, dialysis, and the treatment of thromboembolic disorders. The raw material — crude heparin — is predominantly sourced from porcine intestinal mucosa, making the supply chain highly dependent on a small number of producing countries. Over the 2015–2025 period, the EU's trade in heparin has undergone significant structural changes: a persistent and large trade deficit with the rest of the world, a dramatic geographic reconfiguration of intra-EU trade leadership, and a major build-up of domestic production capacity. This report draws on EU-level trade data for CN 30019091 to describe and interpret these dynamics.

1. A Persistent but Narrowing Trade Deficit

The EU remains structurally dependent on external heparin supply

Throughout the entire period, the EU was a net importer of heparin. In 2015, total imports stood at €924 million while exports reached only €388 million, yielding a trade deficit of €536 million. By 2025, imports had fallen to €523 million and exports to €257 million, narrowing the deficit to €267 million — an improvement of 50.2%. The deficit was at its widest at some point during the period (reaching a maximum of €731 million) before contracting. This persistent deficit reflects the EU's structural reliance on crude heparin sourced from Asia and the Americas for its pharmaceutical manufacturing base.

Source: General Overview — Trade

Import volumes held steady while export volumes collapsed

A striking divergence emerges when looking at physical quantities. EU import volumes were remarkably stable, moving from 325 tonnes to 318 tonnes (−2.0%), suggesting the EU's pharmaceutical sector maintained a consistent demand for raw heparin inputs. By contrast, EU export volumes fell sharply from 285 tonnes to just 86 tonnes (−70.0%). This indicates that the EU increasingly processed imported crude heparin for domestic consumption and re-export in higher-value downstream pharmaceutical forms, rather than re-exporting heparin itself.

Source: General Overview — Trade

Unit prices moved in opposite directions for imports and exports

Import unit prices declined by 42.2% over the period, falling from approximately €2.84 million per tonne to €1.64 million per tonne. This likely reflects a combination of increased global supply (particularly from China and Brazil expanding porcine heparin production) and intensified price competition among suppliers. Meanwhile, export unit prices more than doubled (+120%), rising from €1.36 million per tonne to €2.99 million per tonne. The convergence of export and import unit prices suggests that the EU's remaining heparin exports are increasingly concentrated in higher-purity, higher-value fractions rather than crude bulk material.

2. Geographic Reconfiguration: France's Decline and New EU Trade Hubs

France lost its position as the EU's dominant heparin trading hub

The most dramatic structural shift in the EU heparin market over this decade was the collapse of France's role. France went from being by far the largest EU importer (€574 million, representing over 62% of EU imports) to just €88 million in 2025 (−84.6%). On the export side, France fell from €311 million to €201 million (−35.3%). This decline likely reflects a combination of corporate restructuring (major French pharmaceutical companies restructuring their heparin supply chains) and the redistribution of procurement and processing activities across the EU.

Sources: Imports by reporter, Exports by reporter

Hungary, Italy, and Spain absorbed France's lost import share

Hungary emerged as a major new import hub, growing from €125 million to €196 million (+57.4%), while Italy nearly doubled its imports (€38 million → €71 million, +87.3%) and Spain grew by 53.1%. This redistribution is consistent with the broader trend of pharmaceutical manufacturing capacity shifting within the EU, particularly towards Central and Southern Europe where production costs are lower. Hungary's prominence may also reflect its established role in pharmaceutical manufacturing (several major generic and API producers operate there).

Singapore, the United States, and China dominate extra-EU supply

Singapore was the EU's single largest source of heparin imports (€501 million → €277 million), followed by the United States (€196 million → €96 million) and China (€188 million → €120 million). These three countries together accounted for the vast majority of EU heparin imports. Singapore's prominence is partly explained by its role as a trading hub for Asian-origin heparin, not necessarily as a primary producer. China's share is significant given that it is the world's largest producer of porcine crude heparin, but direct imports from China to the EU declined by 36.4%, suggesting that some procurement has been rerouted through intermediaries.

Source: Imports by partner

Export destinations also shifted, with Singapore absorbing most EU heparin exports

On the export side, Singapore was again the primary destination (€274 million → €197 million), likely serving as a re-distribution point for further processing or re-export to other Asian markets. Exports to the United States, the United Kingdom, and Canada all declined sharply (−77.8%, −87.1%, and −96.4% respectively), while exports to Türkiye grew by 84.9%. The collapse of exports to Canada is particularly notable and may be linked to supply-chain realignments in the North American pharmaceutical sector.

3. Rising Production Capacity, Strategic Autonomy, and Price Shocks

EU production value grew dramatically, tripling over the decade

According to production data, EU heparin production value increased from €674 million to an estimated €2,800 million (+315.6%), peaking at approximately €3,300 million. This extraordinary growth — far exceeding the increase in trade values — points to a substantial expansion of the EU's domestic heparin processing and pharmaceutical formulation industry. It is consistent with increased investment in European API (active pharmaceutical ingredient) manufacturing capacity, partly driven by post-COVID policy emphasis on pharmaceutical supply-chain resilience.

Net import reliance declined, though the EU remains a net importer

The net import reliance indicator — measuring the share of domestic consumption satisfied by net imports — fell from 16.2% to 13.9% over the period, having dipped as low as 8.4% at its minimum. While the EU still depends on external crude heparin supply, the declining trend suggests that the expansion of domestic production has partially offset import needs. Meanwhile, trade intensity (trade as a share of production) remained broadly stable at around 32–34%, and export propensity rose from 11.3% to 13.9%, indicating that the EU is exporting a growing fraction of its production — but to fewer, more concentrated destinations.

Export concentration intensified while import sourcing remained diversified

The Herfindahl-Hirschman Index (HHI) for exports rose from 5,134 to 6,129 (+19.4%), indicating that EU heparin exports became significantly more concentrated in fewer destination markets — primarily Singapore. For imports, the HHI remained relatively stable (3,810 → 3,669, −3.7%), suggesting that while the geographic structure of imports shifted (with France's share declining), the overall level of diversification across suppliers did not change dramatically.

Price shocks affected select export partners

The volatility and shock analysis reveals several notable price shock events in EU heparin exports:

Source: Volatility — Supply shocks

The extreme price spike for Canadian exports in 2019 (+2,425%) and Turkish exports in the same year (+4,311%) likely reflect very small-volume shipments where a shift to higher-purity fractions or specialty formulations produced outsized unit-price changes rather than genuine supply disruptions. The 2020 US price shock (+612.2%) is more significant given the 7.6% value share, and may be linked to COVID-19-related demand surges for anticoagulants (heparin was widely used in COVID-19 treatment protocols for coagulopathy).

Specialisation in heparin production is concentrated in a handful of EU members

In 2025, the most specialised EU exporters of heparin — as measured by revealed symmetric comparative advantage (RSCA) — were Sweden (RSCA = 0.74), Spain (0.70), and Ireland (0.65). These three countries hold strong comparative advantages in heparin and related pharmaceutical products, with their production shares in heparin far exceeding their shares in overall EU exports. By contrast, most other EU member states — including large economies like Germany, Czechia, and Slovakia — showed negative RSCA values, indicating that they are net importers of heparin relative to their overall trade profiles.

Conclusion

Over the 2015–2025 decade, the EU heparin market underwent a fundamental restructuring. While the EU remained a net importer of heparin throughout, the trade deficit narrowed by half as domestic production capacity tripled in value terms. The geographic centre of gravity within the EU shifted decisively away from France — which saw its imports collapse by 85% — towards Hungary, Italy, and Spain. Externally, Singapore remained the dominant partner on both the import and export sides, functioning as a key node in the global heparin supply chain. The EU's increasing specialisation in higher-value heparin fractions is evidenced by diverging unit-price trends: falling import prices alongside rising export prices, even as export volumes declined sharply. The concentration of exports into fewer markets (rising HHI) represents a potential vulnerability, even as import sourcing remained moderately diversified. Looking forward, the combination of growing domestic production, declining net import reliance, and continued expansion by Hungary and Southern European members suggests a gradual strengthening of the EU's strategic position in this critical pharmaceutical supply chain — though dependence on Asian-origin crude heparin raw material remains a structural feature of the market.